Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-15T16:11:54.913Z Has data issue: false hasContentIssue false

P.024 Sex and gender reporting in clinical trials among neurological US Food and Drug Administration approvals

Published online by Cambridge University Press:  24 May 2024

L Cooper-Brown
Affiliation:
(Toronto)*
J Chen
Affiliation:
(Montreal)*
J Chen
Affiliation:
(Hamilton)
A Ebadi
Affiliation:
(Hamilton)
L Wilson
Affiliation:
(Montreal)
J Xie
Affiliation:
(Hamilton)
B Bernhardt
Affiliation:
(Montreal)
E Bui
Affiliation:
(Toronto)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Sex and gender are related but distinct determinants of disease, treatment response, and research reproducibility whose consideration is increasingly required for research funding. Nevertheless, the quality of sex and gender reporting in neurological randomized controlled trials (RCTs) remains unknown. Methods: This ongoing study of RCTs associated with Food and Drug Administration neurological drug approvals aims to determine the frequency of accurate reporting of RCT participants’ sex and gender. Secondary outcomes include changes in reporting over time and RCT design characteristics. Results: Preliminary analysis included 145 RCTs (153,410 participants) associated with 77 medications approved in 1985-2023, most commonly for epilepsy (19%), migraine (16%), and multiple sclerosis (16%). Sixty-six RCTs (45.5%) used sex-related terms appropriately. Nine RCTs (6.2%) reported gender accurately. Fifty-three RCTs (37%) used sex- or gender-related terms interchangeably. There are no statistically significant differences in the proportions of studies reporting sex and/or gender accurately when comparing those published until versus after 2017. No RCT reported sex or gender collection methods, definitions of sex or gender, or including sex or gender minority participants. Conclusions: Preliminary results suggest shortcomings in reporting sex and, especially, gender accurately and inclusively among neurological drug RCTs and no significant improvement thereof in recent years.

Type
Abstracts
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation